I agree on unblinding now, with a caveat


I sent Nader an email last week saying that given all the calculations I've seen, we should have enough wiggle room in the final results to spend the alpha now but who knows if he read it and the statisticians at Amarex know a lot more than any of us.

Of course if the primary endpoint is modified that means mortality is not a reliable standard anymore so taking the penalty in that instance would be foolish.